Search results
Results from the WOW.Com Content Network
Lifileucel is the first tumor-derived T cell immunotherapy approved by the US Food and Drug Administration (FDA). [3] It was approved for medical use in the United States in February 2024. [ 2 ] [ 4 ]
Mavorixafor improved absolute neutrophil counts and absolute lymphocyte counts, assessed over a 24-hour period four times throughout the study. [2] Absolute neutrophil counts below 500 cells/μL and absolute lymphocyte counts below 1000 cells/μL are associated with an increased risk of infections. [ 2 ]
Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system.Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.
Afamitresgene autoleucel is a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved ...
In 2024 the US FDA gave accelerated approval to Lifileucel, the company's tumor-infiltrating lymphocyte drug for the treatment of unresectable or metastatic melanoma. [4]
The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release.
The US Food and Drug Administration on Friday approved the first flu vaccine that does not have to be administered by a health care provider, but it won’t be available in time for this ...
Talquetamab was approved for medical use in both the United States [9] [13] [14] and the European Union [15] in August 2023. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication .